Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients.
about
Tacrolimus in preventing transplant rejection in Chinese patients--optimizing useTemporary Parenteral Tacrolimus Requirement due to Unexplained Low Through Levels in a Liver Transplant Patient with Short Bowel Syndrome.Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients.PharmGKB summary: cyclosporine and tacrolimus pathwaysMechanisms of clinically relevant drug interactions associated with tacrolimus.The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation.Dosing equation for tacrolimus using genetic variants and clinical factorsPopulation pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients.Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant.Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients.Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients.A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach.Therapeutic drug monitoring of tacrolimus in pediatric liver transplant patients.Assessment of myocardial hypertrophy by echocardiography in adult patients receiving tacrolimus or cyclosporine therapy for prevention of acute GVHD.Biodegradable microsphere-loaded tacrolimus enhanced the effect on mice islet allograft and reduced the adverse effect on insulin secretion.Efficacy and pharmacokinetics of tacrolimus oral suspension in pediatric liver transplant recipients.Tacrolimus in pediatric liver transplantation.Two- to three-fold increase in blood tacrolimus (FK506) levels during diarrhea in liver-transplanted children.Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance.The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis.Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions.Standard dosing of tacrolimus leads to overexposure in pediatric renal transplantation recipients.Buccal vs. nasogastric tube administration of tacrolimus after pediatric liver transplantation.
P2860
Q28087131-7AA3C544-D9BD-4D27-882F-16083202B106Q33872062-5C185FB2-8FF0-494D-A074-DBC38AABE6F9Q33888004-C44A8CB1-ACE7-4838-A118-67E4CC2E8599Q33989902-55766435-A6BE-4084-BFDC-BDF2EC9A26C7Q34791985-A2A44971-97B0-4D3F-A028-0C2329B82ACDQ35544537-977B3D7A-8EA7-45C2-9A64-546DAE5278E9Q35629782-7C110E6C-31C2-42AE-8ACA-22867C0C559FQ36055374-449F15A0-8789-4E1C-B93C-2EC59DF8E426Q36125433-A232CD0A-8B29-40AE-9A3D-33A8124B848CQ37207789-3B27D42D-3391-4BD9-B680-11026A7C2C21Q37772515-88BE8416-4A15-44D3-8F2A-B776B865A2EFQ37892910-28942869-08EE-4A5E-A187-0D1622A0E776Q38612229-C9CDE566-FF2D-4BC2-BF3E-2F25AC44A750Q39041618-2F86DD42-940A-4B93-AD33-EBD54996B483Q43592033-C9D23064-9845-40D5-A003-FDAE17BEB57CQ43861731-74EBAACC-95CF-4B5E-997B-38A733B8590BQ43985629-6D359894-517F-4388-A174-577E693D38F1Q43986508-72EBEB70-7508-4C95-BD53-C2F331778727Q44230295-05CDBD78-7919-40E9-AF85-B3373A4CE8ADQ44461528-2A319415-DA8C-4852-A2AD-C57CCE0A16B8Q45749580-C7D434E4-7AAB-4CBE-A355-6947931A8478Q46067187-4F78F237-11C2-4B5E-BA25-249692101E58Q46485596-6B77DBE5-A19F-4D14-8B96-CD7D6A632592Q46627888-8DC10E83-B2E3-492D-A4FD-6B74C87BA88EQ46961883-0903E765-55E4-40AB-87D7-EE5D83E9A3E1
P2860
Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients.
@en
Pharmacokinetics of tacrolimus
@nl
type
label
Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients.
@en
Pharmacokinetics of tacrolimus
@nl
prefLabel
Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients.
@en
Pharmacokinetics of tacrolimus
@nl
P2093
P356
P1476
Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients.
@en
P2093
A M Taburet
I Firdaous
J De Ville De Goyet
L Lykavieris
P2888
P304
P356
10.1007/BF03192295
P577
1998-07-01T00:00:00Z